BERKELEY, Calif., Oct. 13, 2016 /PRNewswire/ -- Steep
Hill, the global leader in cannabis testing and analytics,
today announced it has licensed its cannabis testing technology for
use in Pennsylvania and
Washington, DC to the same highly
respected physician team that operates Steep Hill
Maryland. The lab in Columbia,
MD has been completed and will be ready to test 60 days
before the first batch of medical cannabis will need to be
tested.
Logo - http://photos.prnewswire.com/prnh/20161013/428517LOGO
Dr. Andrew Rosenstein, CEO of
Steep Hill Maryland – and now also CEO of Steep Hill
Pennsylvania and Steep Hill DC – said, "The
professionalism in science and business support that Steep Hill has
provided to us since we signed the licensing deal for Steep Hill
Maryland in May has been extraordinary. The ramp up to launch
is going extremely well, and it has given us the confidence to make
the decision to expand into Pennsylvania and Washington DC, with the goal of being the East
Coast "hub" for Steep Hill. As we expand with Steep
Hill, we are also looking for strong local operating partners
to join our team in Pennsylvania,
and we would encourage interested strategic partners to contact us.
Together we intend to be the gold standard for science, service,
and safety for the medical cannabis industry in Maryland, Pennsylvania, and the District of Columbia."
In making the joint announcement, Steep Hill President
and CEO Jmîchaeĺe Keller said, "Steep Hill is excited not
only to expand our footprint on the East Coast to offer a larger
population base of medical patients access to safe, tested, and
healthy cannabis, but also to strengthen our strong partnership
with Dr. Rosenstein and his highly qualified team of medical
professionals. Together we will deliver the best science,
technology, and professionalism available in cannabis testing for
medical patients in Maryland,
Pennsylvania, and Washington
DC. This marks a new era in cannabis safety for the East
Coast. The Steep Hill East Coast team consists of
doctors, laboratory specialists, and health care experts including
board-certified pathologists, gastroenterologists, and highly
experienced health care business professionals who have years of
experience in patient care and testing human tissue to detect
disease. This highly qualified, physcian-led team will be
intimately involved in setting the standard for cannabis safety in
Maryland, Pennsylvania, and the District of Columbia, and will also work
together with our world class scientists in other states. We plan
to coordinate our shared knowledge of the cannabis plant within the
Steep Hill network globally, while moving the science
forward together."
The Steep Hill Maryland, Steep Hill Pennsylvania,and
Steep Hill DC team is comprised of:
- Dr. Andrew Rosenstein,
CEO, and the Chief of the Division of Gastroenterology at
University of Maryland Saint Joseph
Medical Center. Dr. Rosenstein has been recognized by Baltimore
Magazine as a top doctor in the Baltimore area and has an appointment as an
Assistant Clinical Professor of Gastroenterology and Hepatology at
the University of Maryland Medical
Center.
- Dr. Charles J. Sailey, a
board-certified clinical and Molecular Genetic Pathologist with
medical licenses in several states. He has served as medical and
scientific director of lab departments in molecular genetic
pathology, molecular microbiology, metabolic genetics, toxicology,
and clinical chemistry.
- Dr. Amin Khan, an
experienced board-certified Gastroenterologist/Hepatologist who has
been a Medical Director of a busy ambulatory endoscopy center, a
co-founder of a human tissue diagnostics laboratory, and is the
principal founder and medical director of the innovative reference
laboratory, Integrated Cellular and Molecular Diagnostics
(ICMD).
- Mr. Marc Rosenstein, CPA,
MBA, will serve as CFO, a capacity for which he has previously
served healthcare systems, surgery centers, physician practices and
pathology laboratories.
- Barry F. Pritchard, MBA,
is a technical business development professional having held
executive leadership roles in various technology companies. He is
an American Chemical Society certified chemist with creative skills
in natural products isolation and quantitation. He brings a unique
"Voice of Customer" focus to our operational mission of ensuring
safe and well characterized medicines to the communities we
serve.
For more information about cannabis testing, please visit the
Steep Hill website: http://steephill.com
ABOUT STEEP HILL
Founded in California in 2008, Steep Hill Labs,
Inc. is a science and technology firm that has become the
industry leader in cannabis testing and analytics. Steep Hill
has labs open or in development in seven U.S. states
(Alaska, California, Hawaii, Maryland, New
Mexico, Pennsylvania, and
Washington State), Washington DC, and one country internationally
(Jamaica), with many more to come—
making Steep Hill the largest cannabis lab network in the
world. The company pioneered the first medical cannabis potency and
microbiological contaminants testing methodology for use in
California—the first state to legalize medical cannabis. Steep
Hill has since developed a variety of revolutionary cannabis
testing products, including QuantaCann™, QuantaCann2™ and GenKit™.
Steep Hill provides expert consulting services to many
states, countries and municipalities, and the company is developing
proprietary genetic testing, mapping and trademark protection
services for the industry as well.
Contact: Cathie Bennett Warner
Cell: 415-420-1573
Email
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/steep-hill-announces-significant-east-coast-expansion--licenses-cannabis-testing-laboratories-in-pennsylvania-and-washington-dc-300344583.html
SOURCE Steep Hill